Skip to Main Content

Author Details

James N Ingle
Mayo Clinic
1952
428
87
PMIDPaper TitleJournal TitlePublished Year
36892847Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.JAMA Oncol2023
37072398Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.Nat Commun2023
36469363Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.Cancer Res2023
36709040Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.Ann Oncol2023
36534524Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial.Clin Cancer Res2023
36493334Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.J Clin Oncol2023
34667110Anastrozole Regulates Fatty Acid Synthase in Breast Cancer.Mol Cancer Ther2022
35653140Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer.Clin Cancer Res2022
35734391Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.NAR Cancer2022
35177654Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.NPJ Breast Cancer2022
34825307Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R.Breast Cancer Res Treat2022
32929540Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).Support Care Cancer2021
33627502Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.Mol Cancer Res2021
33766079Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.Breast Cancer Res2021
33674749Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance.Oncogene2021
34078650Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).Clin Cancer Res2021
34001842ZNF423 modulates the AMP-activated protein kinase pathway and metformin response in a single nucleotide polymorphisms, estrogen and selective estrogen receptor modulator dependent fashion.Pharmacogenet Genomics2021
34108182Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.Clin Cancer Res2021
34048027Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.Clin Pharmacol Ther2021
33389409A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.Breast Cancer Res Treat2021
32649577Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.Pharmacogenet Genomics2021
31571071Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues.Breast Cancer Res Treat2020
31693129Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.J Natl Cancer Inst2020
32047850Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.NPJ Breast Cancer2020
32098767Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.Clin Cancer Res2020
31917424Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.JAMA Oncol2020
32701512Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.JCI Insight2020
32433262Baseline estrogen levels in postmenopausal women participating in the MAP.3 breast cancer chemoprevention trial.Menopause2020
32539536Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer.Pharmacogenomics2020
32430040Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.Breast Cancer Res2020
30648747Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.Clin Pharmacol Ther2019
31211741Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.Pharmacogenet Genomics2019
31211604Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.J Clin Oncol2019
31119569Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.Breast Cancer Res Treat2019
30944027The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.Breast Cancer Res2019
309376574-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.Breast Cancer Res Treat2019
28913760Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.Breast Cancer Res Treat2018
29863451Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.N Engl J Med2018
30180881NOTCH3 expression is linked to breast cancer seeding and distant metastasis.Breast Cancer Res2018
30257941ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.Proc Natl Acad Sci U S A2018
30652605PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.JCO Clin Cancer Inform2018
29393405Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells.Oncol Rep2018
29554282Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.J Natl Cancer Inst2018
29385237Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Clin Pharmacol Ther2018
29768301Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.Pharmacogenet Genomics2018
29791287BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.J Clin Oncol2018
29621538Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.Biochem Pharmacol2018
29592948<i>TCL1A</i>, a Novel Transcription Factor and a Coregulator of Nuclear Factor <i>κ</i>B p65: Single Nucleotide Polymorphism and Estrogen Dependence.J Pharmacol Exp Ther2018
29128193Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27.Clin Breast Cancer2018
29328860Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.J Clin Oncol2018
  • 1 - 50 of 428

Recommended Authors

Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 6
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 2
Sharon F McGee
The Ottawa Hospital Cancer Centre
Career Start Year 2006
Number of shared co-authors 0
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 7
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 18
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 6
Lissandra Dal Lago
Institut Jules Bordet
Career Start Year 2002
Number of shared co-authors 5
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 11
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 18
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 12
Eleni Andreopoulou
New York Presbyterian Hospital
Career Start Year 1997
Number of shared co-authors 5
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 15
Carolien P Schr??der
University of Groningen, University Medical Center Groningen
Career Start Year 1995
Number of shared co-authors 4
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 6
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 4
Linda T Vahdat
Dartmouth Cancer Center
Career Start Year 1993
Number of shared co-authors 14
John M S Bartlett
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 16
Powel H Brown
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 10
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 4
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 9
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 19
Caroline Seynaeve
Erasmus Medical Center
Career Start Year 1990
Number of shared co-authors 25
Robert C Stein
12 University College London Hospitals National Health Service Foundation Trust
Career Start Year 1989
Number of shared co-authors 1
Luc Dirix
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 6
Christos Markopoulos
National and Kapodistrian University of Athens
Career Start Year 1987
Number of shared co-authors 1
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 3
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year 1986
Number of shared co-authors 8
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 5
Gottfried E Konecny
David Geffen School of Medicine at University of California Los Angeles
Career Start Year 1984
Number of shared co-authors 19
Dennis J Slamon
David Geffen School of Medicine at university of california los angeles
Career Start Year 1973
Number of shared co-authors 26

Collaborators

Matthew P Goetz
Mayo Clinic
Co-authored papers 90
Vera J Suman
Mayo Clinic
Co-authored papers 70
Richard M Weinshilboum
Mayo Clinic
Co-authored papers 59
Liewei Wang
Mayo Clinic
Co-authored papers 44
Lois Shepherd
Queens University
Co-authored papers 40
Daniel J Schaid
Mayo Clinic
Co-authored papers 36
Kathleen I Pritchard
UCL Great Ormond Street Institute of Child Health, University College London
Co-authored papers 33
Nancy E Davidson
Co-authored papers 30
Fergus J Couch
Mayo Clinic
Co-authored papers 25
Michiaki Kubo
Co-authored papers 19
Judy C Boughey
Mayo Clinic
Co-authored papers 19
Matthew J Ellis
Co-authored papers 17
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 17
Charles L Loprinzi
Mayo Clinic
Co-authored papers 16
Janet E Olson
Mayo Clinic
Co-authored papers 13
Minetta C Liu
Co-authored papers 13
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers 12
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 11
Yusuke Nakamura
Japanese Foundation for Cancer Research
Co-authored papers 11
Gregory D Jenkins
Mayo Clinic
Co-authored papers 10
Charles Kent Osborne
Co-authored papers 10
Amy C Degnim
Mayo Clinic
Co-authored papers 9
Sandhya Pruthi
Mayo Clinic
Co-authored papers 9
Thomas M Pisansky
Mayo Clinic
Co-authored papers 8
Clive S Grant
Inova Health System
Co-authored papers 8
Vered Stearns
Co-authored papers 8
Peter A Fasching
Otto-Friedrich-University Bamberg
Co-authored papers 7
Tanya L Hoskin
Division of Biostatistics and Clinical Trials, Mayo Clinic
Co-authored papers 7
Antonio C Wolff
Co-authored papers 6
Kathleen R Brandt
Mayo Clinic
Co-authored papers 6
Release 1.2